Chiesi submits MAA in Europe for triple combo inhaler

Italian family-owned drugmaker Chiesi Farmaceutici has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for its triple combination for chronic obstructive pulmonary disease (COPD).

This first of its kind combination includes the anti-inflammatory inhaled corticosteroid beclomethasone (ICS), the bronchodilator formoterol, a LABA (a long-acting β2 agonist) and the bronchodilator glycopyrronium, a LAMA (long-acting muscarinic antagonist).

The product has been submitted for the treatment and reduction of exacerbations in adult patients with severe COPD. It is administered by using one single inhaler specifically formulated by Chiesi to deliver extrafine particles to the lungs.